Borderline Personality Disorder: A Dysregulation of the Endogenous Opioid System?

Psychological Review

Volumn 117, Issue 2, 2010, Pages 623-636

  Bandelow, Borwin ^a   Schmahl, Christian ^b   Falkai, Peter ^a   Wedekind, Dirk ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

borderline personality disorder; endogenous opioid system; reward system

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DOPAMINE; SEROTONIN;

ADDICTION; AFFECT; ARTICLE; BORDERLINE STATE; BRAIN; HIGH RISK BEHAVIOR; HUMAN; HUMAN RELATION; METABOLISM; OBJECT RELATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SEXUAL BEHAVIOR; SOCIAL BEHAVIOR;

AFFECT; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; BRAIN; DOPAMINE; HUMANS; INTERPERSONAL RELATIONS; OBJECT ATTACHMENT; RISK-TAKING; SEROTONIN; SEXUAL BEHAVIOR; SOCIAL BEHAVIOR; SUBSTANCE-RELATED DISORDERS;

EID: 77953164170     PISSN: 0033295X     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0018095     Document Type: Article

References (177)

1. Adi Y., Juarez-Garcia A., Wang D., Jowett S., Frew E., Day E., and Burls A. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health Technology Assessment 11 6 (2007) 1-85 iii-iv
2. Aharon I., Etcoff N., Ariely D., Chabris C.F., O'Connor E., and Breiter H.C. Beautiful faces have variable reward value: fMRI and behavioral evidence. Neuron 32 (2001) 537-551
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), Author, Washington, DC
4. Aron A., Fisher H., Mashek D.J., Strong G., Li H., and Brown L.L. Reward, motivation, and emotion systems associated with early-stage intense romantic love. Journal of Neurophysiology 94 (2005) 327-337
5. Avena N.M., Bocarsly M.E., Rada P., Kim A., and Hoebel B.G. After daily bingeing on a sucrose solution, food deprivation induces anxiety and accumbens dopamine/acetylcholine imbalance. Physiology & Behavior 94 (2008) 309-315
6. Bandelow B., Krause J., Wedekind D., Broocks A., Hajak G., and Rüther E. Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Research 134 (2005) 169-179
7. Barbano M.F., and Cador M. Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology (Berlin) 191 (2007) 497-506
8. Barr C.S., Schwandt M.L., Lindell S.G., Higley J.D., Maestripieri D., Goldman D., and Heilig M. Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proceedings of the National Academy of Sciences, USA 105 (2008) 5277-5281
9. Barrera F.J., Teodoro J.M., Selmeci T., and Madappuli A. Self-injury, pain, and the endorphin theory. Journal of Developmental and Physical Disabilities 6 (1994) 169-192
10. Bellino S., Paradiso E., and Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 22 (2008) 671-692
11. Bellis M.A., Hennell T., Lushey C., Hughes K., Tocque K., and Ashton J.R. Elvis to Eminem: Quantifying the price of fame through early mortality of European and North American rock and pop stars. Journal of Epidemiology Community Health 61 (2007) 896-901
12. Bierer L.M., Yehuda R., Schmeidler J., Mitropoulou V., New A.S., Silverman J.M., and Siever L.J. Abuse and neglect in childhood: Relationship to personality disorder diagnoses. CNS Spectrums 8 (2003) 737-754
13. Binks C.A., Fenton M., McCarthy L., Lee T., Adams C.E., and Duggan C. Pharmacological interventions for people with borderline personality disorder [Article CD005653]. Cochrane Database of Systematic Reviews (2006) doi: 10.1002/14651858.CD005653
14. Binks C.A., Fenton M., McCarthy L., Lee T., Adams C.E., and Duggan C. Psychological therapies for people with borderline personality disorder [Article CD005652]. Cochrane Database of Systematic Reviews (2006) doi: 10.1002/14651858.CD005652
15. Black D.W., Gunter T., Allen J., Blum N., Arndt S., Wenman G., and Sieleni B. Borderline personality disorder in male and female offenders newly committed to prison. Comprehensive Psychiatry 48 (2007) 400-405
16. Blood A.J., and Zatorre R.J. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proceedings of the National Academy of Sciences, USA 98 (2001) 11818-11823
17. Boecker H., Sprenger T., Spilker M.E., Henriksen G., Koppenhoefer M., Wagner K.J., and Tolle T.R. The runner's high: Opioidergic mechanisms in the human brain. Cerebral Cortex 18 (2008) 2523-2531
18. Bohus M.J., Landwehrmeyer G.B., Stiglmayr C.E., Limberger M.F., Bohme R., and Schmahl C.G. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: An open-label trial. Journal of Clinical Psychiatry 60 (1999) 598-603
19. Bohus M., Limberger M., Ebner U., Glocker F.X., Schwarz B., Wernz M., and Lieb K. Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior. Psychiatry Research 95 (2000) 251-260
20. Bohus M., Schmahl C., and Lieb K. New developments in the neurobiology of borderline personality disorder. Current Psychiatry Reports 6 1 (2004) 43-50
21. Bostwick J.M., and Bucci J.A. Internet sex addiction treated with naltrexone. Mayo Clinic Proceedings 83 (2008) 226-230
22. Brewer J.A., and Potenza M.N. The neurobiology and genetics of impulse control disorders: Relationships to drug addictions. Biochemical Pharmacology 75 (2008) 63-75
23. Brody S., Potterat J.J., Muth S.Q., and Woodhouse D.E. Psychiatric and characterological factors relevant to excess mortality in a long-term cohort of prostitute women. Journal of Sex and Marital Therapy 31 (2005) 97-112
24. Bullock K., and Koran L. Psychopharmacology of compulsive buying. Drugs of Today (Barcelona) 39 (2003) 695-700
25. Carden S.E., and Hofer M.A. The effects of opioid and benzodiazepine antagonists on dam-induced reductions in rat pup isolation distress. Developmental Psychobiology 23 (1990) 797-808
26. Carr K.D. Feeding, drug abuse, and the sensitization of reward by metabolic need. Neurochemical Research 21 (1996) 1455-1467
27. Charney D., and Bremner D. The neurobiology of anxiety disorders. In: Charney D. (Ed). Neurobiology of mental illness (1999), Oxford University Press, Oxford, England 494-517
28. Chatoor I., Herman B.H., and Hartzler J. Effects of the opiate antagonist, naltrexone, on binging antecedents and plasma beta-endorphin concentrations. Journal of the American Academy of Child and Adolescent Psychiatry 33 (1994) 748-752
29. Chen E.Y., Brown M.Z., Lo T.T., and Linehan M.M. Sexually transmitted disease rates and high-risk sexual behaviors in borderline personality disorder versus borderline personality disorder with substance use disorder. Journal of Nervous and Mental Disease 195 (2007) 125-129
30. Cohen M.R., Pickar D., Extein I., Gold M.S., and Sweeney D.R. Plasma cortisol and beta-endorphin immunoreactivity in nonmajor and major depression. American Journal of Psychiatry 141 (1984) 628-632
31. Coid J., Allolio B., and Rees L.H. Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 322 (1983) 545-546
32. Coid J.W., and Cordess C. Compulsory admission of dangerous psychopaths. British Medical Journal 304 (1992) 1581-1582
33. Couppis M.H., and Kennedy C.H. The rewarding effect of aggression is reduced by nucleus accumbens dopamine receptor antagonism in mice. Psychopharmacology (Berlin) 197 (2008) 449-456
34. Curtin F., and Niveau G. Psychosocial profile of Swiss sexual offenders. Journal of Forensic Sciences 43 (1998) 755-759
35. Darke S., Ross J., Williamson A., and Teesson M. The impact of borderline personality disorder on 12-month outcomes for the treatment of heroin dependence. Addiction 100 (2005) 1121-1130
36. Davidson K., Norrie J., Tyrer P., Gumley A., Tata P., Murray H., and Palmer S. The effectiveness of cognitive behavior therapy for borderline personality disorder: Results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders 20 (2006) 450-465
37. Depue R.A., and Morrone-Strupinsky J.V. A neurobehavioral model of affiliative bonding: Implications for conceptualizing a human trait of affiliation. Behavioral and Brain Sciences 28 3 (2005) 313-350
38. De Vries T.J., and Shippenberg T.S. Neural systems underlying opiate addiction. Journal of Neuroscience 22 (2002) 3321-3325
39. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., and Hamon M. International Union of Pharmacology: XII. Classification of opioid receptors. Pharmacological Reviews 48 (1996) 567-592
40. Ehlers W., and Plassmann R. Diagnosis of narcissistic self-esteem regulation in patients with factitious illness (Munchausen syndrome). Psychotherapy and Psychosomatics 62 (1994) 69-77
41. Eichenberger G.C.D., Ribeiro S.J., Osaki M.Y., Maruoka R.Y., Resende G.C.C., Castellan-Baldan L., and Coimbra N.C. Neuroanatomical and psychopharmacological evidence for interaction between opioid and GABAergic neural pathways in the modulation of fear and defense elicited by electrical and chemical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray matter. Neuropharmacology 42 (2002) 48-59
42. Enoch M.A. The role of GABA(A) receptors in the development of alcoholism. Pharmacology Biochemistry and Behavior 90 (2008) 95-104
43. Esch T., and Stefano G.B. The neurobiology of love. Neuroendocrinology Letters 26 3 (2005) 175-192
44. Essex M.J., Klein M.H., Cho E., and Kalin N.H. Maternal stress beginning in infancy may sensitize children to later stress exposure: Effects on cortisol and behavior. Biological Psychiatry 52 (2002) 776-784
45. Fabre-Nys C., Meller R.E., and Keverne E.B. Opiate antagonists stimulate affiliative behaviour in monkeys. Pharmacology Biochemistry and Behavior 16 (1982) 653-659
46. Fossati A., Madeddu F., and Maffei C. Borderline personality disorder and childhood sexual abuse: A meta-analytic study. Journal of Personality Disorders 13 (1999) 268-280
47. Fountoulakis K.N., Leucht S., and Kaprinis G.S. Personality disorders and violence. Current Opinion in Psychiatry 21 (2008) 84-92
48. Friedel R.O. Dopamine dysfunction in borderline personality disorder: A hypothesis. Neuropsychopharmacology 29 (2004) 1029-1039
49. Gade K., Haussinger C., and Bandelow B. Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone. Pharmacopsychiatry 42 (2009) 164-165
50. Goldfarb A.H., and Jamurtas A.Z. Beta-endorphin response to exercise: An update. Sports Medicine 24 1 (1997) 8-16
51. Goodman M., and Yehuda R. The relationship between psychological trauma and borderline personality disorder. Psychiatric Annals 32 (2002) 337-346
52. Gorman J.M., Kent J.M., Sullivan G.M., and Coplan J.D. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 157 (2000) 493-505
53. Grant B.F., Chou S.P., Goldstein R.B., Huang B., Stinson F.S., Saha T.D., and Ruan W.J. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: Results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 69 (2008) 533-545
54. Grant J.E., and Kim S.W. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Annals of Clinical Psychiatry 13 (2001) 229-231
55. Grant J.E., and Kim S.W. An open-label study of naltrexone in the treatment of kleptomania. Journal of Clinical Psychiatry 63 (2002) 349-356
56. Grant J.E., Kim S.W., and Hartman B.K. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. Journal of Clinical Psychiatry 69 (2008) 783-789
57. Grant J.E., Kim S.W., and Odlaug B.L. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biological Psychiatry 65 (2009) 600-606
58. Grant J.E., Potenza M.N., Hollander E., Cunningham-Williams R., Nurminen T., Smits G., and Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. American Journal of Psychiatry 163 (2006) 303-312
59. Gross-Isseroff R., Dillon K.A., Israeli M., and Biegon A. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Research 530 (1990) 312-316
60. Halfon O., Laget J., and Barrie M. An epidemiological and clinical approach to adolescent suicide: A comparison between suicidal and non-suicidal clinical groups in a health foundation center for French students. European Child and Adolescent Psychiatry 4 1 (1995) 32-38
61. Hatzitaskos P., Soldatos C.R., Kokkevi A., and Stefanis C.N. Substance abuse patterns and their association with psychopathology and type of hostility in male patients with borderline and antisocial personality disorder. Comprehensive Psychiatry 40 (1999) 278-282
62. Heinze M., Andreae D., and Grohmann R. Pharmacotherapy of personality disorders in German speaking countries: State and changes in the last decade. Pharmacopsychiatry 38 (2005) 201-205
63. Hennig J., Laschefski U., and Opper C. Biopsychological changes after bungee jumping: Beta-endorphin immunoreactivity as a mediator of euphoria?. Neuropsychobiology 29 (1994) 28-32
64. Herpertz S. Self-injurious behaviour: Psychopathological and nosological characteristics in subtypes of self-injurers. Acta Psychiatrica Scandinavica 91 (1995) 57-68
65. Herpertz S.C., Zanarini M., Schulz C.S., Siever L., Lieb K., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World Journal of Biological Psychiatry 8 (2007) 212-244
66. Hersh E.V., Ochs H., Quinn P., MacAfee K., Cooper S.A., and Barasch A. Narcotic receptor blockade and its effect on the analgesic response to placebo and ibuprofen after oral surgery. Oral Surgery, Oral Medicine, Oral Pathology 75 (1993) 539-546
67. Hill A., Habermann N., Berner W., and Briken P. Psychiatric disorders in single and multiple sexual murderers. Psychopathology 40 (2007) 22-28
68. Holstege G., Georgiadis J.R., Paans A.M., Meiners L.C., van der Graaf F.H., and Reinders A.A. Brain activation during human male ejaculation. Journal of Neuroscience 23 (2003) 9185-9193
69. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., and Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258 (1975, December 18) 577-580
70. Huseman C.A., Pearson P.H., Madison J., and Leuschen M.P. Bulimia as a form of self-addiction: Treatment with naltrexone hydrochloride (Trexan)-a pilot study. Clinical Trials Journal 27 2 (1990) 77-83
71. Ikemoto S., and Wise R.A. Mapping of chemical trigger zones for reward. Neuropharmacology 47 Suppl. 1 (2004) 190-201
72. Inch H., and Huws R. Tattooed female psychiatric patients. British Journal of Psychiatry 163 (1993) 127-128
73. Ishikawa A., Ambroggi F., Nicola S.M., and Fields H.L. Dorsomedial prefrontal cortex contribution to behavioral and nucleus accumbens neuronal responses to incentive cues. Journal of Neuroscience 28 (2008) 5088-5098
74. Johansen O., Brox J., and Flaten M.A. Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosomatic Medicine 65 (2003) 786-790
75. Jonas J.M., and Gold M.S. Treatment of antidepressant-resistant bulimia with naltrexone. International Journal of Psychiatry in Medicine 16 (1986) 305-309
76. Kaffman A., and Meaney M.J. Neurodevelopmental sequelae of postnatal maternal care in rodents: Clinical and research implications of molecular insights. Journal of Child Psychology and Psychiatry and Allied Disciplines 48 (2007) 224-244
77. Kalin N.H., Shelton S.E., and Lynn D.E. Opiate systems in mother and infant primates coordinate intimate contact during reunion. Psychoneuroendocrinology 20 (1995) 735-742
78. Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiology and Behavior 94 (2008) 121-135
79. Kaye W.H., Pickar D., Naber D., and Ebert M.H. Cerebrospinal fluid opioid activity in anorexia nervosa. American Journal of Psychiatry 139 (1982) 643-645
80. Kelley A.E., and Berridge K.C. The neuroscience of natural rewards: Relevance to addictive drugs. Journal of Neuroscience 22 (2002) 3306-3311
81. Kemperman I., Russ M.J., Clark W.C., Kakuma T., Zanine E., and Harrison K. Pain assessment in self-injurious patients with borderline personality disorder using signal detection theory. Psychiatry Research 70 (1997) 175-183
82. Kim S.W., and Grant J.E. An open naltrexone treatment study in pathological gambling disorder. International Clinical Psychopharmacology 16 (2001) 285-289
83. Kim S.W., Grant J.E., Adson D.E., and Shin Y.C. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry 49 (2001) 914-921
84. Klein D.A., Bennett A.S., Schebendach J., Foltin R.W., Devlin M.J., and Walsh B.T. Exercise "addiction" in anorexia nervosa: Model development and pilot data. CNS Spectrums 9 (2004) 531-537
85. Kleindienst N., Bohus M., Ludäscher P., Limberger M.F., Kuenkele K., Ebner-Priemer U.W., and Schmahl C. Motives for nonsuicidal self-injury among women with borderline personality disorder. Journal of Nervous and Mental Disease 196 (2008) 230-236
86. Klonsky E.D., and Moyer A. Childhood sexual abuse and non-suicidal self-injury: Meta-analysis. British Journal of Psychiatry 192 (2008) 166-170
87. Knowles P.A., Conner R.L., and Panksepp J. Opiate effects on social behavior of juvenile dogs as a function of social deprivation. Pharmacology Biochemistry and Behavior 33 (1989) 533-537
88. Knutson B., Adams C.M., Fong G.W., and Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. Journal of Neuroscience 21 (2001) RC159
89. Komaki G., Tamai H., Sumioki H., Mori T., Kobayashi N., Mori K., and Nakagawa T. Plasma beta-endorphin during fasting in man. Hormone Research 33 (1990) 239-243
90. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., and Fehr E. Oxytocin increases trust in humans. Nature 435 (2005, June 2) 673-676
91. Kumor K., Su T.P., Vaupel B., Haertzen C., Johnson R.E., and Goldberg S. Studies of kappa agonist. Nida Research Monograph 67 (1986) 18-25
92. Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs 22 (2008) 407-416
93. LeDoux J. Fear and the brain: Where have we been, and where are we going?. Biological Psychiatry 44 (1998) 1229-1238
94. Lever J.R. PET and SPECT imaging of the opioid system: Receptors, radioligands and avenues for drug discovery and development. Current Pharmaceutical Design 13 (2007) 33-49
95. Levine J.D., Gordon N.C., and Fields H.L. The mechanism of placebo analgesia. Lancet 2 (1978) 654-657
96. Linehan M.M., Tutek D.A., Heard H.L., and Armstrong H.E. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry 151 (1994) 1771-1776
97. Ludäscher P., Bohus M., Lieb K., Philipsen A., Jochims A., and Schmahl C. Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder. Psychiatry Research 149 (2007) 291-296
98. Ludolph P.S., Westen D., Misle B., Jackson A., Wixom J., and Wiss F.C. The borderline diagnosis in adolescents: Symptoms and developmental history. American Journal of Psychiatry 147 (1990) 470-476
99. Markoff R.A., Ryan P., and Young T. Endorphins and mood changes in long-distance running. Medicine and Science in Sports and Exercise 14 (1982) 11-15
100. Marrazzi M.A., Bacon J.P., Kinzie J., and Luby E.D. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. International Clinical Psychopharmacology 10 (1995) 163-172
101. Marrazzi M.A., and Luby E.D. An auto-addiction opioid model of chronic anorexia nervosa. International Journal of Eating Disorders 5 (1986) 191-208
102. Marrazzi M.A., Luby E.D., Kinzie J., Munjal I.D., and Spector S. Endogenous codeine and morphine in anorexia and bulimia nervosa. Life Sciences 60 (1997) 1741-1747
103. Martin-Soelch C., Chevalley A.F., Künig G., Missimer J., Magyar S., Mino A., and Leenders K.L. Changes in reward-induced brain activation in opiate addicts. European Journal of Neuroscience 14 (2001) 1360-1368
104. Martin-Soelch C., Leenders K.L., Chevalley A.F., Missimer J., Künig G., Magyar S., and Schultz W. Reward mechanisms in the brain and their role in dependence: Evidence from neurophysiological and neuroimaging studies. Brain Research Reviews 36 (2001) 139-149
105. Matthews R.T., and German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 11 (1984) 617-625
106. McEwen B.S., and Sapolsky R.M. Stress and cognitive function. Current Opinion in Neurobiology 5 (1995) 205-216
107. McGee M.D. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry 58 (1997) 32-33
108. Melis M.R., Melis T., Cocco C., Succu S., Sanna F., Pillolla G., and Argiolas A. Oxytocin injected into the ventral tegmental area induces penile erection and increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the hypothalamus of male rats. European Journal of Neuroscience 26 (2007) 1026-1035
109. Mitchell J.E., Christenson G., Jennings J., Huber M., Thomas B., Pomeroy C., and Morley J. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. Journal of Clinical Psychopharmacology 9 (1989) 94-97
110. Moles A., Kieffer B.L., and D'Amato F.R. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 304 (2004, June 25) 1983-1986
111. Moll J., Krueger F., Zahn R., Pardini M., de Oliveira-Souza R., and Grafman J. Human fronto-mesolimbic networks guide decisions about charitable donation. Proceedings of the National Academy of Sciences, USA 103 (2006) 15623-15628
112. Naltrexone hydrochloride tablets package insert (2003), Mallinckrodt, St. Louis, MO
113. Narayanan S., Lam H., Christian L., Levine M.S., Grandy D., Rubinstein M., and Maidment N.T. Endogenous opioids mediate basal hedonic tone independent of dopamine d-1 or d-2 receptor activation. Neuroscience 124 (2004) 241-246
114. Nestler E.J. The neurobiology of cocaine addiction. Science & Practice Perspectives 3 1 (2005) 4-10
115. New A.S., Goodman M., Triebwasser J., and Siever L.J. Recent advances in the biological study of personality disorders. Psychiatric Clinics of North America 31 (2008) 441-461
116. New A.S., Triebwasser J., and Charney D.S. The case for shifting borderline personality disorder to Axis I. Biological Psychiatry 64 (2008) 653-659
117. Nomikos G.G., Damsma G., Wenkstern D., and Fibiger H.C. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6 (1990) 106-112
118. Nuller Y.L., Morozova M.G., Kushnir O.N., and Hamper N. Effect of naloxone therapy on depersonalization: A pilot study. Journal of Psychopharmacology 15 (2001) 93-95
119. Odent M. The scientification of love (1999), Free Association Books, London, United Kingdom
120. Olds J., and Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. Journal of Comparative and Physiological Psychology 47 (1954) 419-427
121. Panksepp J., Herman B., Conner R., Bishop P., and Scott J.P. The biology of social attachments: Opiates alleviate separation distress. Biological Psychiatry 13 (1978) 607-618
122. Papezova H., Yamamotova A., and Uher R. Elevated pain threshold in eating disorders: Physiological and psychological factors. Journal of Psychiatric Research 39 (2005) 431-438
123. Paris J. Clinical trials of treatment for personality disorders. Psychiatric Clinics of North America 31 (2008) 517-526
124. Paris J. The treatment of borderline personality disorder: Implications of research on diagnosis, etiology, and outcome. Annual Review of Clinical Psychology 5 (2009) 277-290 doi: 10.1146/annurev.clinpsy.032408.153457
125. Paris J., Zweig-Frank H., and Guzder J. Risk factors for borderline personality in male outpatients. Journal of Nervous and Mental Disease 182 (1994) 375-380
126. Perkins D.O., Davidson E.J., Leserman J., Liao D., and Evans D.L. Personality disorder in patients infected with HIV: A controlled study with implications for clinical care. American Journal of Psychiatry 150 (1993) 309-315
127. Pert C.B., and Snyder S.H. Opiate receptor: Demonstration in nervous tissue. Science 179 (1973, March 9) 1011-1014
128. Pfaus J.G., Damsma G., Nomikos G.G., Wenkstern D.G., Blaha C.D., Phillips A.G., and Fibiger H.C. Sexual behavior enhances central dopamine transmission in the male rat. Brain Research 530 (1990) 345-348
129. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986, August 15) 774-776
130. Philipsen A., Schmahl C., and Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37 (2004) 196-199
131. Ravert H.T., Bencherif B., Madar I., and Frost J.J. PET imaging of opioid receptors in pain: Progress and new directions. Current Pharmaceutical Design 10 7 (2004) 759-768
132. Raymond N.C., Grant J.E., Kim S.W., and Coleman E. Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: Two case studies. International Clinical Psychopharmacology 17 (2002) 201-205
133. Roth A.S., Ostroff R.B., and Hoffman R.E. Naltrexone as a treatment for repetitive self-injurious behaviour: An open-label trial. Journal of Clinical Psychiatry 57 (1996) 233-237
134. Roth-Deri I., Green-Sadan T., and Yadid G. Beta-endorphin and drug-induced reward and reinforcement. Progress in Neurobiology 86 (2008) 1-21
135. Roth-Deri I., Zangen A., Aleli M., Goelman R.G., Pelled G., Nakash R., and Yadid G. Effect of experimenter-delivered and self-administered cocaine on extracellular β-endorphin levels in the nucleus accumbens. Journal of Neurochemistry 84 (2003) 930-938
136. Russ M.J., Roth S.D., Lerman A., Kakuma T., Harrison K., Shindledecker R.D., and Marris S. Pain perception in self-injurious patients with borderline personality disorder. Biological Psychiatry 32 (1992) 501-511
137. Ryback R.S. Naltrexone in the treatment of adolescent sexual offenders. Journal of Clinical Psychiatry 65 (2004) 982-986
138. Sacco P., Cunningham-Williams R.M., Ostmann E., and Spitznagel Jr. E.L. The association between gambling pathology and personality disorders. Journal of Psychiatric Research 42 (2008) 1122-1130
139. Sahley T.L., and Panksepp J. Brain opioids and autism: An updated analysis of possible linkages. Journal of Autism and Developmental Disorders 17 (1987) 201-216
140. Sandman C.A., Touchette P.E., Marion S.D., and Chicz-DeMet A. The role of proopiomelanocortin (POMC) in sequentially dependent self-injurious behavior. Developmental Psychobiology 50 (2008) 680-689
141. Saper J.R., and Lake III A.E. Borderline personality disorder and the chronic headache patient: Review and management recommendations. Headache 42 (2002) 663-674
142. Schlaepfer T.E., Cohen M.X., Frick C., Kosel M., Brodesser D., Axmacher N., and Sturm V. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33 (2008) 368-377
143. Schlaepfer T.E., Strain E.C., Greenberg B.D., Preston K.L., Lancaster E., Bigelow G.E., and Pearlson G.D. Site of opioid action in the human brain: Mu and kappa agonists' subjective and cerebral blood flow effects. American Journal of Psychiatry 155 (1998) 470-473
144. Schmahl C., Bohus M., Esposito F., Treede R.-D., Di Salle F., Greffrath W., and Seifritz E. Neural correlates of antinociception in borderline personality disorder. Archives of General Psychiatry 63 (2006) 659-667
145. Schmahl C., and Bremner J.D. Neuroimaging in borderline personality disorder. Journal of Psychiatric Research 40 (2006) 419-427
146. Schmahl C., Greffrath W., Baumgärtner U., Schlereth T., Magerl W., Philipsen A., and Treede R.-D. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: Laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain 110 (2004) 470-479
147. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
148. Schulz S.C., Cornelius J., Schulz P.M., and Soloff P.H. The amphetamine challenge test in patients with borderline disorder. American Journal of Psychiatry 145 (1988) 809-814
149. Schulz S.C., Schulz P.M., Dommisse C., Hamer R.M., Blackard W.G., Narasimhachari N., and Friedel R.O. Amphetamine response in borderline patients. Psychiatry Research 15 (1985) 97-108
150. Shinohara K., Yanagisawa A., Kagota Y., Gomi A., Nemoto K., Moriya E., and Teresawa K. Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate. Applied Human Science 18 (1999) 37-42
151. Shizgal P., and Arvanitogiannis A. Neuroscience: Gambling on dopamine. Science 299 (2003, March 21) 1856-1858
152. Silk K.R. Borderline personality disorder: Overview of biologic factors. Psychiatric Clinics of North America 23 (2000) 61-75
153. Simeon D., and Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. Journal of Clinical Psychopharmacology 25 (2005) 267-270
154. Sonne S., Rubey R., Brady K., Malcolm R., and Morris T. Naltrexone treatment of self-injurious thoughts and behaviors. Journal of Nervous and Mental Disease 184 (1996) 192-195
155. Steffensen S.C., Walton C.H., Hansen D.M., Yorgason J.T., Gallegos R.A., and Criado J.R. Contingent and non-contingent effects of low-dose ethanol on GABA neuron activity in the ventral tegmental area. Pharmacology Biochemistry and Behavior 92 (2009) 68-75
156. Stewart J. Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacology Biochemistry and Behavior 20 (1984) 917-923
157. Streeton C., and Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism 36 (2001) 544-552
158. Sweep C.G., Van Ree J.M., and Wiegant V.M. Characterization of beta-endorphin-immunoreactivity in limbic brain structures of rats self-administering heroin or cocaine. Neuropeptides 12 (1988) 229-236
159. Symons F.J., Thompson A., and Rodriguez M.C. Self-injurious behavior and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews 10 (2004) 193-200
160. Timmerman I.G., and Emmelkamp P.M. The relationship between traumatic experiences, dissociation, and borderline personality pathology among male forensic patients and prisoners. Journal of Personality Disorders 15 (2001) 136-149
161. Tordjman S., Carlier M., Cohen D., Cesselin F., Bourgoin S., Colas-Linhart N., and Roubertoux P.L. Aggression and the three opioid families (endorphins, enkephalins, and dynorphins) in mice. Behavior Genetics 33 (2003) 529-536
162. Torgersen S., Lygren S., Øien P.A., Skre I., Onstad S., Edvardsen J., and Kringlen E. A twin study of personality disorders. Comprehensive Psychiatry 41 (2000) 416-425
163. Vaanholt L.M., Turek F.W., and Meerlo P. Beta-endorphin modulates the acute response to a social conflict in male mice but does not play a role in stress-induced changes in sleep. Brain Research 978 (2003) 169-176
164. van Erp A.M., and Miczek K.A. Aggressive behavior, increased accumbal dopamine, and decreased cortical serotonin in rats. Journal of Neuroscience 20 (2000) 9320-9325
165. van Ree J.M. Reinforcing stimulus properties of drugs. Neuropharmacology 18 (1979) 963-969
166. 2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. American Journal of Psychiatry 158 (2001) 2015-2021
167. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berlin) 157 (2001) 151-162
168. Wedekind D., Bandelow B., and Ruther E. Pharmakotherapie bei Persönlichkeitsstörungen [Pharmacotherapy in personality disorders]. Fortschritte der Neurologie-Psychiatrie 73 (2005) 259-267
169. Wedekind, D., Becker, J., Bandelow, B., & Falkai, P. (2009). Current pharmacological treatment of borderline personality disorder. Manuscript submitted for publication.
170. Weinberg I., Gunderson J.G., Hennen J., and Cutter Jr. C.J. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders 20 (2006) 482-492
171. Williams J.R., Insel T.R., Harbaugh C.R., and Carter C.S. Oxytocin administered centrally facilitates formation of a partner preference in female prairie voles (Microtus ochrogaster). Journal of Neuroendocrinology 6 (1994) 247-250
172. Zanarini M.C., Frankenburg F.R., Hennen J., Reich D.B., and Silk K.R. Prediction of the 10-year course of borderline personality disorder. American Journal of Psychiatry 163 (2006) 827-832
173. Zanarini M.C., Frankenburg F.R., Hennen J., and Silk K.R. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. American Journal of Psychiatry 160 (2003) 274-283
174. Zanarini M.C., Frankenburg F.R., Hennen J., and Silk K.R. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Journal of Clinical Psychiatry 65 (2004) 28-36
175. Zanarini M.C., Reichman C.A., Frankenburg F.R., Reich D.B., and Fitzmaurice G. The course of eating disorders in patients with borderline personality disorder: A 10-year follow-up study. International Journal of Eating Disorders (2009) Advance online publication. doi: 10.1002/eat.20689
176. Zeki S. The neurobiology of love. FEBS Letters 581 (2007) 2575-2579
177. Zubieta J.K., Gorelick D.A., Stauffer R., Ravert H.T., Dannals R.F., and Frost J.J. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature Medicine 2 (1996) 1225-1229